Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April W Armstrong

Showing results (331-340 of 522) with videos related to

Pageof 53
Sort By:
Respiratory Medicine|July 4, 2024
Prevalence, incidence, and risk of chronic obstructive pulmonary disease among psoriasis patientsLily Guo, Sara N Bilimoria, Robin Kikuchi, et al.
Lancet (London, England)|August 13, 2019
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trialKristian Reich, April W Armstrong, Richard G Langley, et al.
JAMA Dermatology|October 20, 2021
Bullous Dermatoses and Depression: A Systematic ReviewSarah P Pourali, Yasmin Gutierrez, Alison H Kucharik, et al.
JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
The Journal of Investigative Dermatology|November 10, 2024
Chronic Obstructive Pulmonary Disease Outcomes in Patients with PsoriasisLily Guo, Sara N Bilimoria, Robin Kikuchi, et al.
Dermatology and Therapy|April 24, 2026
Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims AnalysisApril W Armstrong, Rebecca Burne, Aseel Bin Sawad, et al.
Dermatology and Therapy|July 21, 2022
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic ArthritisGeorge Gondo, Megan Mosca, Julie Hong, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Journal of the American Academy of Dermatology|September 21, 2021
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United StatesJoseph F Merola, Haijun Tian, Dhaval Patil, et al.
Pageof 53

Showing results (331-340 of 522) with videos related to

Sort By:
Pageof 53
Respiratory Medicine|July 4, 2024
Prevalence, incidence, and risk of chronic obstructive pulmonary disease among psoriasis patientsLily Guo, Sara N Bilimoria, Robin Kikuchi, et al.
Lancet (London, England)|August 13, 2019
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trialKristian Reich, April W Armstrong, Richard G Langley, et al.
JAMA Dermatology|October 20, 2021
Bullous Dermatoses and Depression: A Systematic ReviewSarah P Pourali, Yasmin Gutierrez, Alison H Kucharik, et al.
JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
The Journal of Investigative Dermatology|November 10, 2024
Chronic Obstructive Pulmonary Disease Outcomes in Patients with PsoriasisLily Guo, Sara N Bilimoria, Robin Kikuchi, et al.
Dermatology and Therapy|April 24, 2026
Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims AnalysisApril W Armstrong, Rebecca Burne, Aseel Bin Sawad, et al.
Dermatology and Therapy|July 21, 2022
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic ArthritisGeorge Gondo, Megan Mosca, Julie Hong, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Journal of the American Academy of Dermatology|September 21, 2021
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United StatesJoseph F Merola, Haijun Tian, Dhaval Patil, et al.
Pageof 53